- Investing Ideas
- /
- Global High Growth Potential Companies
Global High Growth Potential Companies
Results
8551
0 new
Companies with a Future performance score of at least 3, ordered by Future performance score.
8,551 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
HTL | PK₨39.19 | 2.4% | 66.7% | PK₨5.5b | PK₨63.60 | PB1x | E48.3% | 0% | Capital Goods | ||
YGG | ฿0.96 | -5.0% | -87.3% | ฿577.9m | ฿10.75 | PS2x | E85.5% | 27.9% | Media | ||
9992 | HK$49.05 | 1.6% | 108.3% | HK$65.0b | HK$53.34 | PE38.8x | E29.0% | 0.6% | Retail | ||
6181 | HK$108.30 | 15.8% | n/a | HK$18.2b | HK$119.37 | PE20.6x | E34.7% | n/a | Consumer Durables | ||
505283 | ₹1,313.80 | 4.7% | 119.1% | ₹85.1b | ₹1,706.50 | PE59.9x | E30.1% | 0.5% | Capital Goods | ||
533286 | ₹393.40 | -0.7% | 70.3% | ₹80.1b | ₹485.00 | PE22.3x | E36.5% | 1.5% | Materials | ||
ACI | ₹710.15 | -2.5% | 14.6% | ₹87.6b | ₹878.71 | PE32.5x | E33.7% | 0.4% | Materials | ||
NYKAA | ₹207.69 | -3.6% | 38.4% | ₹593.4b | ₹199.96 | PE1537.1x | E36.9% | n/a | Retail | ||
DOMS | ₹2,810.85 | 6.7% | n/a | ₹170.6b | ₹2,523.33 | PE100.1x | E20.1% | 0.09% | Commercial Services | ||
ARES | US$143.84 | 2.0% | 37.0% | US$44.3b | US$150.23 | PE75.9x | E32.9% | 2.6% | Diversified Financials | ||
ZVRA | US$7.59 | 5.0% | 48.2% | US$388.8m | US$18.00 | PS16.9x | E69.4% | n/a | Pharmaceuticals & Biotech | ||
CADLR | NOK 70.20 | 4.8% | 79.6% | NOK 24.6b | NOK 81.94 | PS16.9x | E67.8% | n/a | Capital Goods | ||
AFISH | NOK 46.40 | -2.1% | -50.6% | NOK 1.5b | NOK 81.00 | PS1.5x | E98.9% | n/a | Food, Beverage & Tobacco | ||
MVW | NOK 10.60 | -4.5% | 15.0% | NOK 346.8m | NOK 12.20 | PS20.2x | E71.6% | n/a | Materials | ||
CALTX | SEK 207.40 | 0.1% | 138.5% | SEK 11.2b | SEK 227.50 | PS7x | E51.9% | n/a | Pharmaceuticals & Biotech | ||
TVTX | US$12.60 | 26.9% | -8.6% | US$936.3m | US$17.40 | PS5.4x | E68.8% | n/a | Pharmaceuticals & Biotech | ||
GGP | UK£0.052 | -26.5% | -24.9% | UK£263.7m | n/a | PB5.3x | E48.8% | n/a | Materials | ||
AOT | CA$0.16 | -63.6% | -62.8% | CA$113.0m | n/a | PS46.7x | E46.9% | n/a | Materials | ||
GAU | CA$1.99 | 9.9% | 134.1% | CA$493.3m | CA$3.30 | PE38.8x | E31.2% | n/a | Materials | ||
RHM | €521.80 | 1.3% | 103.2% | €22.7b | €616.44 | PE34.7x | E27.7% | 1.1% | Capital Goods | ||
ASND | US$113.81 | -4.4% | 10.1% | US$6.5b | US$182.64 | PS18.6x | E68.4% | n/a | Pharmaceuticals & Biotech | ||
AGP | €6.62 | -1.5% | 63.1% | €114.6m | €12.75 | PE23.3x | E22.8% | n/a | Capital Goods | ||
TGTX | US$23.19 | 8.1% | 127.6% | US$3.3b | US$33.75 | PE34.8x | E43.5% | n/a | Pharmaceuticals & Biotech | ||
RMDA | ج.م2.57 | -0.4% | 74.7% | ج.م3.9b | ج.م4.38 | PE17x | E30.3% | 2.6% | Pharmaceuticals & Biotech |